Evidence map›Paper›PMID 36533625›Full record

ArticleJournal of the American Heart Association2022

Imène Mansouri, Jeremie Botton, Laura Semenzato, Nadia Haddy, Mahmoud Zureik

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Uncovering hypothesis-generating associations between prescription drugs and digestive cancer risk: a case-control drug-wide association study (DWAS).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  2. Observational
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Imène MansouriEPI-PHARE (French National Agency for Medicines and Health Products Safety [ANSM] and French National Health Insurance [CNAM]) Saint-Denis France.ORCID 0000-0001-6811-8695
Jeremie BottonEPI-PHARE (French National Agency for Medicines and Health Products Safety [ANSM] and French National Health Insurance [CNAM]) Saint-Denis France.ORCID 0000-0002-4814-6370
Laura SemenzatoEPI-PHARE (French National Agency for Medicines and Health Products Safety [ANSM] and French National Health Insurance [CNAM]) Saint-Denis France.ORCID 0000-0002-8305-3487
Nadia HaddyCenter for Research Epidemiology and Population Health (CESP), Radiation Epidemiology Team Université Paris-Saclay, Université Paris-Sud, UVSQ Villejuif France.
Mahmoud ZureikEPI-PHARE (French National Agency for Medicines and Health Products Safety [ANSM] and French National Health Insurance [CNAM]) Saint-Denis France.
Conservatoire National des Arts et Métiers · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Since July 2018, numerous lots of valsartan have been found to be contaminated with

Indexed as

Liver NeoplasmsMelanomaAdultAgedAged, 80 and overDimethylnitrosamineDrug ContaminationHumansMiddle AgedValsartanDimethylnitrosamineValsartanhealth claims dataliver cancermelanomaN‐nitrosodimethylamine (NDMA)valsartan

Identifiers

PMID36533625
PMCPMC9798794
OpenAlexW4312093739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.